View More View Less
  • 1 Pécsi Tudományegyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Pécs Ifjúság u. 13. 7624
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A hepatitis C-vírus-infekció jelenlegi terápiája a hazánkban és Európában is domináns HCV1 genotípus fertőzés esetén 40–45%-ban vezet tartós virológiai remisszióhoz. Ugyanakkor a kezelés általában hosszan tartó, költséges és jelentős mellékhatásokkal is jár. Mindez indokolja azokat az intenzív kutatásokat, amelyeknek a célja új, hatékonyabb terápiás eljárások kifejlesztése. Az utolsó 5 évben jelentős haladás történt ezen a téren, egyrészt a HCV életciklusának megismerését, másrészt ezzel együtt a HCV-specifikus direkt ható antivirális ágensek, elsősorban pedig a proteáz- és polimerázgátló vegyületek felfedezését illetően. Az adatok arra utalnak, hogy az új készítmények, elsősorban a proteáz- és polimerázgátlók, az eddigi interferon plusz ribavirin alapú kezeléssel hármas kombinációkban áttörést jelenthetnek. A közeljövőben ily módon várhatóan rövidebb időtartamú terápia alatt jobb gyógyulási arány érhető el még a „nehezen gyógyítható” HCV1-betegekben is. A dolgozat ezekről a lehetőségekről ad áttekintést. Orv. Hetil., 2010, 151, 2045–2056.

  • Fehér J., Lengyel G.: A krónikus C vírushepatitis kezelése. Orv. Hetil., 2004, 145, 1065–1067.

    Lengyel G. , 'A krónikus C vírushepatitis kezelése ' (2004 ) 145 Orv. Hetil. : 1065 -1067.

  • Tornai I., Dalmi L., Gervain J. és mtsai: A pegilált interferon-alfa-2a és ribavirinkezelés hatékonysága krónikus C-vírus-hepatitises betegeken. Az első hazai tapasztalatok egy multicentrikus, nyílt, prospektív vizsgálat alapján. LAM, 2005, 15, 807–813.

    Gervain J. , 'A pegilált interferon-alfa-2a és ribavirinkezelés hatékonysága krónikus C-vírus-hepatitises betegeken. Az első hazai tapasztalatok egy multicentrikus, nyílt, prospektív vizsgálat alapján ' (2005 ) 15 LAM : 807 -813.

    • Search Google Scholar
  • Pár A., Tornai I., Szalay F. és a Vírushepatitis Centrumok Munkacsoportja: A krónikus B- és C-vírushepatitis antivirális kezelésének hazai tapasztalatai (1998–2004). Orv. Hetil., 2007, 148, 819–826.

    Szalay F. , 'A krónikus B- és C-vírushepatitis antivirális kezelésének hazai tapasztalatai (1998–2004) ' (2007 ) 148 Orv. Hetil. : 819 -826.

    • Search Google Scholar
  • Pár A.: A terápiás válasz prediktív tényezői krónikus vírushepatitisekben. LAM, 2008, 18, 841–846.

    Pár A. , 'A terápiás válasz prediktív tényezői krónikus vírushepatitisekben ' (2008 ) 18 LAM : 841 -846.

    • Search Google Scholar
  • Tusnádi A., Szabó A.: A peginterfon alfa-2a vagy -2b plusz ribavirin terápia hatékonysága a krónikus C-vírus hepatitis kezelésének mindennapos gyakorlatában. LAM, 2009, 19, 39–44.

    Szabó A. , 'A peginterfon alfa-2a vagy -2b plusz ribavirin terápia hatékonysága a krónikus C-vírus hepatitis kezelésének mindennapos gyakorlatában ' (2009 ) 19 LAM : 39 -44.

    • Search Google Scholar
  • Hunyady B., Szinku Zs., Haragh A.: A krónikus C-vírus-hepatitis víruskinetika alapján individualizált kezelése hepatológiai ambulanciánkon. LAM, 2009, 19, 193–196.

    Haragh A. , 'A krónikus C-vírus-hepatitis víruskinetika alapján individualizált kezelése hepatológiai ambulanciánkon ' (2009 ) 19 LAM : 193 -196.

    • Search Google Scholar
  • Tornai I.: A krónikus C-vírus-hepatitis peginterferonkezelése. Peginterferon alfa-2a vagy alfa-2b? LAM, 2010, 20, 361–365.

    Tornai I. , 'A krónikus C-vírus-hepatitis peginterferonkezelése. Peginterferon alfa-2a vagy alfa-2b? ' (2010 ) 20 LAM : 361 -365.

    • Search Google Scholar
  • Kronenberg, B., Welsch, C., Forestier, N. és mtsai: Novel hepatitis C drugs in current trials. Clin. Liver Dis., 2008, 12, 529–555.

    Forestier N. , 'Novel hepatitis C drugs in current trials ' (2008 ) 12 Clin. Liver Dis. : 529 -555.

    • Search Google Scholar
  • Asselah, T., Benhamou, Y., Marcellin, P.: Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Internat., 2009, 29, 57–67.

    Marcellin P. , 'Protease and polymerase inhibitors for the treatment of hepatitis C ' (2009 ) 29 Liver Internat. : 57 -67.

    • Search Google Scholar
  • Thompson, A., Patel, K., Tillman, H. és mtsa: Directly acting antivirals for the treatment of patients with hepatitis C infection: A clinical development update addressing key future challenges. J. Hepatol., 2009, 50, 184–194.

    Tillman H. , 'Directly acting antivirals for the treatment of patients with hepatitis C infection: A clinical development update addressing key future challenges ' (2009 ) 50 J. Hepatol. : 184 -194.

    • Search Google Scholar
  • Lange, C., Sarazzin, C.: New agents for treating hepatitis C. In: Hepatology – a clinical textbook. Eds: Maus, S., Berg, T., Rockstroh, J., Sarazzin, C., Wedemeyer, H. Second edition. Flying Publisher, Dusseldorf, 2010, 197–230.

    Sarazzin C. , '', in Hepatology – a clinical textbook , (2010 ) -.

  • Pawlotsky, J. M., Chevaliez, S., McHutchison, J. G.: The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology, 2007, 132, 1979–1998.

    McHutchison J. G. , 'The hepatitis C virus life cycle as a target for new antiviral therapies ' (2007 ) 132 Gastroenterology : 1979 -1998.

    • Search Google Scholar
  • Kupfer, B.: HCV-virology. In: Hepatology – a clinical textbook. Eds: Maus, S., Berg, T., Rockstroh, J., Sarazzin, C., Wedemeyer, H. Second edition. Flying Publisher, Dusseldorf, 2010, 61–82.

    Kupfer B. , '', in Hepatology – a clinical textbook , (2010 ) -.

  • Flisiak, R., Feinman, S. V., Jablkowski, M. és mtsai: The cyclophillin inhibitor Debio 025 combined with PEG-IFN alpha-2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology, 2009, 49, 1460–1468.

    Jablkowski M. , 'The cyclophillin inhibitor Debio 025 combined with PEG-IFN alpha-2a significantly reduces viral load in treatment-naive hepatitis C patients ' (2009 ) 49 Hepatology : 1460 -1468.

    • Search Google Scholar
  • Reesink, H. W., Zeuzem, S., Weegink, C. J. és mtsai: Rapid decline or viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomised study. Gastroenterology, 2006, 131, 997–1002.

    Weegink C. J. , 'Rapid decline or viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomised study ' (2006 ) 131 Gastroenterology : 997 -1002.

    • Search Google Scholar
  • Forestier, N., Reesink, H. W., Weegink, C. J. és mtsai: Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology, 2007, 46, 640–648.

    Weegink C. J. , 'Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C ' (2007 ) 46 Hepatology : 640 -648.

    • Search Google Scholar
  • Lawitz, E., Rodriguez-Torres, M., Muir, A. J. és mtsai: Antiviral effects and safety of telaprevir, peginterferon alfa-2a and ribavirin for 28 days in hepatitis C patients. J. Hepatol., 2008, 49, 163–169.

    Muir A. J. , 'Antiviral effects and safety of telaprevir, peginterferon alfa-2a and ribavirin for 28 days in hepatitis C patients ' (2008 ) 49 J. Hepatol. : 163 -169.

    • Search Google Scholar
  • McHutchison, J. G., Everson, G. T., Gordon, S. C. és mtsai: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med., 2009, 360, 1827–1838.

    Gordon S. C. , 'Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection ' (2009 ) 360 N. Engl. J. Med. : 1827 -1838.

    • Search Google Scholar
  • Hezode, C., Forestier, N., Dusheiko, G. és mtsai: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med., 2009, 360, 1839–1850.

    Dusheiko G. , 'Telaprevir and peginterferon with or without ribavirin for chronic HCV infection ' (2009 ) 360 N. Engl. J. Med. : 1839 -1850.

    • Search Google Scholar
  • McHutchison, J. G., Manns, M. P., Muir, A. J. és mtsai: Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med., 2010, 362, 1292–1302.

    Muir A. J. , 'Telaprevir for previously treated chronic HCV infection ' (2010 ) 362 N. Engl. J. Med. : 1292 -1302.

    • Search Google Scholar
  • Manns, M. P., Muir, G. J., Adda, N. és mtsai: Improved sustained virological response rates in difficult to cure patients treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: an analysis from the PROVE3 study. J. Hepatol., 2010, 52, S115.

    Adda N. , 'Improved sustained virological response rates in difficult to cure patients treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: an analysis from the PROVE3 study ' (2010 ) 52 J. Hepatol. : S115 -.

    • Search Google Scholar
  • Vertex press release. May 25, 2010. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=473342

  • Vertex press release. August 10, 2010. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=497942

  • Vertex press release. Sept 7, 2010. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=505239

  • Zeuzem, S., Sarazzin, C., Wagner, F. és mtsai: Antiviral activity of SCH 503034, a HCV protease inhibitor administered as monotherapy in hepatitis C genotype 1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN alfa). Hepatology, 2005, 42, 276A.

    Wagner F. , 'Antiviral activity of SCH 503034, a HCV protease inhibitor administered as monotherapy in hepatitis C genotype 1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN alfa) ' (2005 ) 42 Hepatology : 276A -.

    • Search Google Scholar
  • Sarrazzin, C., Rouzier, R., Wagner, F. és mtsai: SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegilated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology, 2007, 132, 1270–1278.

    Wagner F. , 'SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegilated interferon alpha-2b for genotype 1 nonresponders ' (2007 ) 132 Gastroenterology : 1270 -1278.

    • Search Google Scholar
  • Kwo, P., Lawitz, E. J., McCone, J. és mtsa: HCV SRINT-1: Boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. Hepatology, 2008, 48, S372.

    McCone J. , 'HCV SRINT-1: Boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients ' (2008 ) 48 Hepatology : S372 -.

    • Search Google Scholar
  • Schiff, E., Poordad, F., Jacobson, I. és mtsai: Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. J. Hepatol., 2008, 48, 104.

    Jacobson I. , 'Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness ' (2008 ) 48 J. Hepatol. : 104 -.

    • Search Google Scholar
  • Forestier, N., Larrey, D. G., Guyader, D. és mtsai: Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/NS4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. Hepatology, 2008, 48, 1132A.

    Guyader D. , 'Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/NS4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study ' (2008 ) 48 Hepatology : 1132A -.

    • Search Google Scholar
  • Gane, E. J., Roberts, S. K., Stedman, C. és mtsai: First-In-Man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: Safety, Pharmacokinetics and virologic results from INFORM-1. J. Hepatology, 2009, 50, S380.

    Stedman C. , 'First-In-Man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: Safety, Pharmacokinetics and virologic results from INFORM-1 ' (2009 ) 50 J. Hepatology : S380 -.

    • Search Google Scholar
  • Forestier, N., Larrey, D., Marcellin, P. és mtsai: Antiviral activity and safety of ITM-191 in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV). J. Hepatol., 2009, 50, S85.

    Marcellin P. , 'Antiviral activity and safety of ITM-191 in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) ' (2009 ) 50 J. Hepatol. : S85 -.

    • Search Google Scholar
  • Manns, M. P., Reesink, H. W., Moreno, C. és mtsai: Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients. Hepatology, 2008, 48, LB8.

    Moreno C. , 'Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients ' (2008 ) 48 Hepatology : LB8 -.

    • Search Google Scholar
  • Manns, M. P., Bourlière, M., Benhamou, Y. és mtsai: Safety ad antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa 2a and ribavirin. Hepatology, 2008, 48, A1849.

    Benhamou Y. , 'Safety ad antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa 2a and ribavirin ' (2008 ) 48 Hepatology : A1849 -.

    • Search Google Scholar
  • Manns, M. P., Bourlière, M., Benhamou, Y. és mtsai: Safety ad antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype-1 infection. Hepatology, 2008, 48, A1882.

    Benhamou Y. , 'Safety ad antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype-1 infection ' (2008 ) 48 Hepatology : A1882 -.

    • Search Google Scholar
  • Sulkowski, M., Bourliere, M., Bronowicki, J-P. és mtsai: SILEN-C2: Early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (PEGIFN/RBV) in chronic HCV genotype1 patients with non-response to PEGIFN/RBV. J. Hepatol., 2010, 52, S462.

    Bronowicki J-P. , 'SILEN-C2: Early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (PEGIFN/RBV) in chronic HCV genotype1 patients with non-response to PEGIFN/RBV ' (2010 ) 52 J. Hepatol. : S462 -.

    • Search Google Scholar
  • Wright, D., Miller, J. L., Valentine, J. és mtsai: Safety, tolerability and pharmacokinetic data following single- and multiple-dose administration on MK-7009, a hepatitis C virus non-structural 3/4A protease inhibitor, to healthy male subjects. Hepatology, 2008, 48, A1910.

    Valentine J. , 'Safety, tolerability and pharmacokinetic data following single- and multiple-dose administration on MK-7009, a hepatitis C virus non-structural 3/4A protease inhibitor, to healthy male subjects ' (2008 ) 48 Hepatology : A1910 -.

    • Search Google Scholar
  • Sarrazin, C., Kieffer, T. L., Bartels, D. és mtsai: Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with protease inhibitor telaprevir. Gastroenterology, 2007, 132, 1767–1777.

    Bartels D. , 'Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with protease inhibitor telaprevir ' (2007 ) 132 Gastroenterology : 1767 -1777.

    • Search Google Scholar
  • Pharmasset Inc. Pharmasset announces R1728 achieves 85% rapid virological response in a 4-week combination study for the treatment of chronic hepatitis C (press release). 7 January, 2008.

  • Gane, E. J., Rodriguez-Torres, M., Nelson, D. R. és mtsai: Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days. Hepatology, 2008, 48, 1024A.

    Nelson D. R. , 'Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days ' (2008 ) 48 Hepatology : 1024A -.

    • Search Google Scholar
  • Lalezari, J., Gane, E., Rodriguez-Torres, M. és mtsai: Potent antiviral activity of the HCV nucleosid polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days. J. Hepatol., 2008, 48, A66.

    Rodriguez-Torres M. , 'Potent antiviral activity of the HCV nucleosid polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days ' (2008 ) 48 J. Hepatol. : A66 -.

    • Search Google Scholar
  • Hammond, J. L., Purohit, V. S., Fang, J. és mtsai: Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor PF-00868554 following multiple dose administration in healthy volunteers. Hepatology, 2008, 48, 1898.

    Fang J. , 'Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor PF-00868554 following multiple dose administration in healthy volunteers ' (2008 ) 48 Hepatology : 1898 -.

    • Search Google Scholar
  • Villano, S., Raible, D., Harper, D. és mtsai: Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination wirh pegylated interferon alfa-2b in treatment-naive patients with chronic HCV. J. Hepatol., 2007, 46, 24.

    Harper D. , 'Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination wirh pegylated interferon alfa-2b in treatment-naive patients with chronic HCV ' (2007 ) 46 J. Hepatol. : 24 -.

    • Search Google Scholar
  • Cooper, C., Lawitz, E. J., Ghali, P. és mtsai: Antiviral activity of the non-nucleosid polymerase inhibitor, VCH-759, in chronic hepatitis C patients: results from a randomized, double-blind, placebo-contolled ascending multiple dose study. Hepatology, 2007, 46, LB11.

    Ghali P. , 'Antiviral activity of the non-nucleosid polymerase inhibitor, VCH-759, in chronic hepatitis C patients: results from a randomized, double-blind, placebo-contolled ascending multiple dose study ' (2007 ) 46 Hepatology : LB11 -.

    • Search Google Scholar
  • Pol, S., Everson, G., Ghalib, R. és mtsai: Once daily NS5A inhibitor (BMS-790052) plus peginterferon-alfa-2a and ribavirin produces high rates of extended rapid virological response in treatment-naive HCV1 genotype subjects: phase 2A trial. J. Hepatol., 2010, 52, S462.

    Ghalib R. , 'Once daily NS5A inhibitor (BMS-790052) plus peginterferon-alfa-2a and ribavirin produces high rates of extended rapid virological response in treatment-naive HCV1 genotype subjects: phase 2A trial ' (2010 ) 52 J. Hepatol. : S462 -.

    • Search Google Scholar
  • Zeuzem, S., Yoshida, E., Benhamou, Y. és mtsai: Sustained virologic response rates with albinterferon alfa-2b plus ribavirin treatment in IFN-native, chronic hepatitis C genotype 1 patients. Hepatology, 2008, 48, 407–417.

    Benhamou Y. , 'Sustained virologic response rates with albinterferon alfa-2b plus ribavirin treatment in IFN-native, chronic hepatitis C genotype 1 patients ' (2008 ) 48 Hepatology : 407 -417.

    • Search Google Scholar
  • Sulkowski, M., Zeuzem, S., Lawitz, E. és mtsai: Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naive patients with HCV genotype 1. Hepatology, 2009, 50, 333.

    Lawitz E. , 'Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naive patients with HCV genotype 1 ' (2009 ) 50 Hepatology : 333 -.

    • Search Google Scholar
  • Hermann, E., Zeuzem, S., Dzyublyk, I. és mtsai: Viral kinetics during treatment with a controlled-release recombinant interferon alfa 2b in genotype 1 chronic hepatitis C patients. J. Hepatol., 2008, 48, 318.

    Dzyublyk I. , 'Viral kinetics during treatment with a controlled-release recombinant interferon alfa 2b in genotype 1 chronic hepatitis C patients ' (2008 ) 48 J. Hepatol. : 318 -.

    • Search Google Scholar
  • Ge, D., Fellay, J., Thompson, A. J. és mtsai: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009, 461, 339–401.

    Thompson A. J. , 'Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance ' (2009 ) 461 Nature : 339 -401.

    • Search Google Scholar
  • Muir, A., Shiffman, M. L., Zaman, A. és mtsai: A phase 1b dose-ranging study of 4 weeks of peg-interferon lambda in combination with ribavirin in patients with chronic hepatitis C virus infection. Hepatology, 2009, 50, 1591.

    Zaman A. , 'A phase 1b dose-ranging study of 4 weeks of peg-interferon lambda in combination with ribavirin in patients with chronic hepatitis C virus infection ' (2009 ) 50 Hepatology : 1591 -.

    • Search Google Scholar
  • Benhamou, Y., Afhdal, N. H., Nelson, D. R. és mtsai: A phase II study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: VISER1 results. Hepatology, 2009, 50, 717–726.

    Nelson D. R. , 'A phase II study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: VISER1 results ' (2009 ) 50 Hepatology : 717 -726.

    • Search Google Scholar
  • Poordad, F., Lawitz, E., Hassanein, T. és mtsai: Sustained virologic response (SVR) results for weight-based taribavirin versus weight-based ribavirin in naive chronic hepatitis C, genotype 1 patients. Hepatology, 2009, 50, 334.

    Hassanein T. , 'Sustained virologic response (SVR) results for weight-based taribavirin versus weight-based ribavirin in naive chronic hepatitis C, genotype 1 patients ' (2009 ) 50 Hepatology : 334 -.

    • Search Google Scholar
  • Poordad, F., Lawitz, E., Shiffman, M. L.: Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients With genotype 1 chronic hepatitis C. Hepatology, 2010, 52, 1208–1215.

    Shiffman M. L. , 'Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients With genotype 1 chronic hepatitis C ' (2010 ) 52 Hepatology : 1208 -1215.

    • Search Google Scholar
  • Kaita, K., Yoshida, E., Kunimoto, S. és mtsai: Phase II proof of concept study of celgovisir in combination with peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 non-responder patients. J. Hepatol., 2007, 46, 56–57.

    Kunimoto S. , 'Phase II proof of concept study of celgovisir in combination with peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 non-responder patients ' (2007 ) 46 J. Hepatol. : 56 -57.

    • Search Google Scholar
  • Elazar, M., Liu, M., McKenna, S. A. és mtsai: The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNS activation. Gastroenterology, 2009, 137, 1827–1835.

    McKenna S. A. , 'The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNS activation ' (2009 ) 137 Gastroenterology : 1827 -1835.

    • Search Google Scholar
  • Bacon, B., Shiffman, M., Lim, J. és mtsai: Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: interim analysis shows increase in EVR. J. Hepatol., 2009, 50 (Suppl. 1), 381.

    Lim J. , 'Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: interim analysis shows increase in EVR ' (2009 ) 50 J. Hepatol. : 381 -.

    • Search Google Scholar
  • Bacon, B., Shiffman, M., Lim, J. és mtsai: Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: week 12 sustained virological response rate. J. Hepatol., 2010, 52, S463.

    Lim J. , 'Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: week 12 sustained virological response rate ' (2010 ) 52 J. Hepatol. : S463 -.

    • Search Google Scholar
  • Polyak, S. J., Morishima, C., Shuart, M. C. és mtsai: Inhibition of T-cell inflammatory cytokines, hepatocyte NF-κB signaling, and HCV infection by standardized silymarin. Gastroenterology, 2007, 132, 1925–1936.

    Shuart M. C. , 'Inhibition of T-cell inflammatory cytokines, hepatocyte NF-κB signaling, and HCV infection by standardized silymarin ' (2007 ) 132 Gastroenterology : 1925 -1936.

    • Search Google Scholar
  • Ferenci, P., Scherzer, T. M., Hofer, A. és mtsai: Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to antiviral combination therapy. J. Hepatology, 2008, 48, S28.

    Hofer A. , 'Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to antiviral combination therapy ' (2008 ) 48 J. Hepatology : S28 -.

    • Search Google Scholar
  • Pár, A., Rőth, E., Miseta, A. és mtsai: Effects of Silymarin supplementation in patients with chronic hepatitis C receiving PEG-IFN+ribavirin antiviral therapy. A placebo-controlled double-blind study. Clin. Exp. Med. J., 2009, 3, 119–129.

    Miseta A. , 'Effects of Silymarin supplementation in patients with chronic hepatitis C receiving PEG-IFN+ribavirin antiviral therapy. A placebo-controlled double-blind study ' (2009 ) 3 Clin. Exp. Med. J. : 119 -129.

    • Search Google Scholar
  • Wedemeyer, H., Van Vlieberghe, H., Blum, H. és mtsai: E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: results of a 15-month, placebo-controlled trial. J. Hepatology, 2006, 42, S229.

    Blum H. , 'E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: results of a 15-month, placebo-controlled trial ' (2006 ) 42 J. Hepatology : S229 -.

    • Search Google Scholar
  • Wedemeyer, H., Schuller, E., Schlaphoff, V. és mtsai: Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine, 2009, 27, 5142–5151.

    Schlaphoff V. , 'Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C ' (2009 ) 27 Vaccine : 5142 -5151.

    • Search Google Scholar